Shareholder Class Action

WILMINGTON, Del. – Directors are selling Avanir Pharmaceuticals too cheaply through an unfair process to Otsuka Pharmaceutical, for $17 a share or $3.5 billion, shareholders claim in Chancery Court.

Exit mobile version